This is a preview of subscription content, log in via an institution to check access.
Notes
2018 US dollars
Reference
El-Dahiyat F, et al. Cost-Minimization Analysis of Ranibizumab Versus Aflibercept for Treating Saudi Patients With Visual Impairment Owing to Age-Related Macular Degeneration or Diabetic Macular Edema. Value in Health Regional Issues : 1 Apr 2020. Available from: URL: https://doi.org/10.1016/j.vhri.2019.09.007
Rights and permissions
About this article
Cite this article
Aflibercept cost saving versus ranibizumab for macular disorders. PharmacoEcon Outcomes News 851, 1 (2020). https://doi.org/10.1007/s40274-020-6724-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6724-6